Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$5.28 USD
-0.06 (-1.12%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $5.28 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.28 USD
-0.06 (-1.12%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $5.28 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Zacks News
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
by Zacks Equity Research
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.
Oracle (ORCL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Oracle's (ORCL) fiscal second-quarter 2024 performance is expected to have benefited from continued demand for cloud infrastructure services.
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Semtech's (SMTC) third-quarter fiscal 2024 results are expected to reflect solid momentum in the industrial market amid macroeconomic challenges.
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
What's in Store for Patterson Companies (PDCO) in Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
by Zacks Equity Research
Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.
Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Aldeyra Therapeutics, Inc. (ALDX) points to a 107.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate
by Zacks Equity Research
Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
by Zacks Equity Research
Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
by Zacks Equity Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Palatin (PTN) Begins Phase III Study For Dry Eye Disease
by Zacks Equity Research
Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.
Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Implied Volatility Surging for Aldeyra (ALDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.